Lys110
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys110  -  NRF2 (human)

Site Information
SQVAHIPkSDALYFD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1877458700

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 , 2 ) , mass spectrometry ( 2 ) , mutation of modification site ( 1 , 2 ) , western blotting ( 1 , 2 )
Disease tissue studied:
liver cancer ( 2 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on NRF2:
intracellular localization ( 2 )
Effects of modification on biological processes:
carcinogenesis, induced ( 2 ) , cell adhesion, inhibited ( 1 ) , cell growth, induced ( 2 ) , cell motility, inhibited ( 1 ) , transcription, induced ( 1 , 2 )

References 

1

Xu J, et al. (2020) Mild Oxidative Stress Reduces NRF2 SUMOylation to Promote // Mutant Lung Adenocarcinoma Cell Migration and Invasion. Oxid Med Cell Longev 2020, 6240125
33299528   Curated Info

2

Guo H, et al. (2019) NRF2 SUMOylation promotes de novo serine synthesis and maintains HCC tumorigenesis. Cancer Lett 466, 39-48
31546024   Curated Info